Return to homepagePandemic Pact

Niclosamide Formulations for the Treatment of Influenza Infections

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R43AI167394-01

Grant search

Key facts

  • Disease

    Unspecified

  • Start & end year

    2022
    2023

  • Known Financial Commitments (USD)

    $298,479

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    PRESIDENT Gary Fujii

  • Research Location

    United States of America

  • Lead Research Institution

    MOLECULAR EXPRESS, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Project Summary The principal goal of this project is to demonstrate that the FDA-approved anthelminthic drug, niclosamide, can be reformulated in a synthetic lung surfactant which can be aerosolized for the treatment of infections caused by respiratory viruses. The studies proposed in this SBIR Phase I application will be focused on testing this concept by suspending niclosamide loaded liposomes in our proprietary lung surfactant technology (Niclosurf) and testing candidate Niclosurf formulations in a mouse influenza challenge model. The effectiveness of Niclosurf as a treatment for respiratory viral infections caused by influenza will be evaluated.